Gene · 9134
Papers2,792
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,792
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. | MedComm (2020) | 2023 | 37143582 | PubTator, text mining | PubMed |
| Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review. | Cancer Med | 2023 | 37132286 | PubTator, text mining | PubMed |
| Primary and Secondary micro-RNA Modulation the Extrinsic Pathway of Apoptosis in Hepatocellular Carcinoma. | Mol Biol | 2023 | 37128213 | PubTator, text mining | PubMed |
| Identification of miRNAs and target genes associated with lymph node metastasis in cervical cancer using bioinformatics analysis. | Toxicol Mech Methods | 2023 | 37125668 | PubTator, text mining | PubMed |
| NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma. | iScience | 2023 | 37123230 | PubTator, text mining | PubMed |
| Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma. | World J Gastrointest Oncol | 2023 | 37123057 | PubTator, text mining | PubMed |
| SALL4 correlates with proliferation, metastasis, and poor prognosis in prostate cancer by affecting MAPK pathway. | Cancer Med | 2023 | 37119046 | PubTator, text mining | PubMed |
| Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects. | Molecules | 2023 | 37110858 | PubTator, text mining | PubMed |
| Tumor suppressive functions of hsa‑miR‑34a on cell cycle, migration and protective autophagy in bladder cancer. | Int J Oncol | 2023 | 37083075 | PubTator, text mining | PubMed |
| Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway. | Drug Dev Res | 2023 | 37070571 | PubTator, text mining | PubMed |
| Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations. | J Enzyme Inhib Med Chem | 2023 | 37070569 | PubTator, text mining | PubMed |
| Identification and Validation of Cyclin A2 and Cyclin E2 as Potential Biomarkers in Small Cell Lung Cancer. | Oncol Res Treat | 2023 | 37062286 | PubTator, text mining | PubMed |
| AMPK activation protects against prostate cancer by inducing a catabolic cellular state. | Cell Rep | 2023 | 37061917 | PubTator, text mining | PubMed |
| Pan-cancer landscape of CENPO and its underlying mechanism in LUAD. | Respir Res | 2023 | 37061713 | PubTator, text mining | PubMed |
| Synthesis and biological evaluation of novel pteridin-7(8H)-one derivatives as potent CDK2 inhibitors. | Bioorg Med Chem Lett | 2023 | 37060933 | PubTator, text mining | PubMed |
| TRPM2 regulates cell cycle through the Ca2+-CaM-CaMKII signaling pathway to promote HCC. | Hepatol Commun | 2023 | 37058100 | PubTator, text mining | PubMed |
| Activin and BMP Signalling in Human Testicular Cancer Cell Lines, and a Role for the Nucleocytoplasmic Transport Protein Importin-5 in Their Crosstalk. | Cells | 2023 | 37048077 | PubTator, text mining | PubMed |
| Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting. | Cancers (Basel) | 2023 | 37046848 | PubTator, text mining | PubMed |
| Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives. | Cancers (Basel) | 2023 | 37046789 | PubTator, text mining | PubMed |
| Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer. | Cell Death Differ | 2023 | 37041291 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9134/papers?page=13